This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Livestro, D. P. Articles by Tanabe, K. K. Search for Related Content PubMed PubMed Citation Articles by Livestro, D. P. Articles by Tanabe, K. K. Social Bookmarking                            What's this?

Biology of Desmoplastic Melanoma: A Case-Control Comparison With Other Melanomas

From the Departments of Surgery, Biostatistics, Dermatology, and Pathology, Massachusetts General Hospital, Boston, MA; and the Faculty of Medicine, University Medical Center, Utrecht, the Netherlands

Address reprint requests to Kenneth K. Tanabe, MD, Division of Surgical Oncology, Cox Building, Rm 626, Massachusetts General Hospital, 100 Blossom St, Boston, MA, 02114; e-mail: ktanabe{at}partners.org

PURPOSE: Previous studies have established that patients with desmoplastic melanoma (DM) have thicker primary tumors. Consequently, comparisons with other forms of melanoma have been strongly biased by differences in Breslow stage. This is the first case-matched control study comparing DM with other forms of melanoma.

PATIENTS AND METHODS: From a database of 3,202 melanoma patients treated at one institution, 89 patients with DM and 178 case-matched control patients (2:1) were identified by matching for tumor thickness, age, sex, and year of diagnosis. Clinical, pathologic, and outcome information was obtained from chart review.

RESULTS: Controls were matched successfully to patients for tumor thickness, age, sex, and year of diagnosis. Presentation with American Joint Committee on Cancer stage III or IV disease is less common in patients with DM compared to case-matched control patients (5% v 21%; P < .001). Re-excisions to obtain clear surgical margins are required more often in patients with DM compared to case-matched control patients (21% v 6%; P < .001). Risk of positive sentinel nodes is lower in patients with DM compared to case-matched control patients (8% v 34%; P = .013). Despite these differences, survival rates of patients with DM are the same as case-matched control patients.

CONCLUSION: Use of case-matched control patients matched for tumor thickness avoids biases introduced by the advanced Breslow stage of DMs. DMs are more locally aggressive than thickness-matched controls, and positive sentinel nodes are limited to patients with thick primary tumors. Importantly, patients with DM have survival rates similar to patients with other melanomas of similar thickness.

D.P.L. was supported in part by a scholarship from the Dutch Cancer Society.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. N. Markovic, L. A. Erickson, R. D. Rao, R. R. McWilliams, L. A. Kottschade, E. T. Creagan, R. H. Weenig, J. L. Hand, M. R. Pittelkow, B. A. Pockaj, et al. Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis Mayo Clin. Proc., March 1, 2007; 82(3): 364 - 380. [Abstract] [Full Text] [PDF]

				J. Rangel, S. Torabian, L. Shaikh, M. Nosrati, F. L. Baehner, C. Haqq, S. P.L. Leong, J. R. Miller III, R. W. Sagebiel, and M. Kashani-Sabet Prognostic Significance of Nuclear Receptor Coactivator-3 Overexpression in Primary Cutaneous Melanoma J. Clin. Oncol., October 1, 2006; 24(28): 4565 - 4569. [Abstract] [Full Text] [PDF]

				H. M. Shaw, M. J. Quinn, R. A. Scolyer, and J. F. Thompson Survival in Patients With Desmoplastic Melanoma J. Clin. Oncol., March 10, 2006; 24(8): e12 - e12. [Full Text] [PDF]

				D. P. Livestro, A. Sober, and K. K. Tanabe In Reply: J. Clin. Oncol., March 10, 2006; 24(8): e13 - e13. [Full Text] [PDF]